90
Participants
Start Date
March 31, 2011
Primary Completion Date
June 26, 2014
Study Completion Date
June 21, 2017
FG-3019
Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
FG-3019
Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
Mount Sinai, New York
Inova Fairfax Hospital, Falls Church
Emory University, Atlanta
Central Florida Pulmonary Group, PA, Orlando
Tampa General Hospital, Tampa
University of Alabama at Birmingham Hospital, Birmingham
Vanderbilt University, Nashville
University of Louisville, Louisville
The Ohio State University, Columbus
University of Wisconsin School of Medicine & Public Health, Madison
St. Luke's Hospital, Chesterfield
Via Christi Hospitals Wichita, Inc., Wichita
University of Texas Southwestern Medical Center, Dallas
University of Utah - Lung Health Research, Salt Lake City
Arizona Pulmonary Specialists, LTD, Scottsdale
Yale University, New Haven
Rutgers-Robert Wood Johnson Medical School, New Brunswick
Vermont Lung Center, Colchester
Lead Sponsor
FibroGen
INDUSTRY